Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2152W HIGH $9.33
Volume
380.01 K
Value Traded
373.59 K
Short % Float
4.36%
+4.87%Week
+24.56%1 Month
+4.72%3 Month
-3.53%6 Month
+17.14%5 Year
+17.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
90.42 M
EPS (TTM)
-0.61
P/E Ratio
-
Ent. Value
79.25 M
Total Shares
12.56 M
Float Shares
8.55 M
Insiders
31.94%
Institutions
23.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NRXS Catalyst Timeline
Dated clinical, regulatory and corporate events for Neuraxis, Inc.
Past FDA Catalysts and PDUFA Decisions
How NRXS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Neuraxis, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NRXS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IB-Stim | pediatric disorders of gut-brain interaction | 2024-03-27 | total patients: 292; failed medications: 92%; failed four or more medications: 61%; improvement after 4 weeks: significant; p value 6 months: <0.001; p value 12 months: <0.001Read More | NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center RegistryRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Henrichs Timothy RobertOfficer (Chief Financial Officer) | Buy | 1,937 9,530 held | $4.84 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NRXS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NRXS for Q2 2026. | ||||
NRXS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NRXS ranks across every disease it competes in
Competitive Position is a premium feature
See how NRXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNRXS News
NRXS▲ +10.6%today
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
NeurAxis, Inc. has announced a major medical policy coverage milestone, expanding access to its IB-Stim technology for an additional 26 million lives. This coverage is significant as it addresses a critical unmet need for pediatric patients suffering from functional abdominal pain. The company is also enhancing its commercial strategy to capitalize on this expansion and anticipates further growth in insurance coverage.
Read more →NRXSNeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
NeurAxis, Inc. has appointed Craig Blanchard as Chief Commercial Officer to lead its commercial functions, including sales and marketing. This strategic move aims to enhance the company's growth potential and expand its market presence for the IB-Stim device, which is FDA-cleared for treating functional abdominal pain in pediatric patients. Blanchard's extensive experience in commercialization and healthcare technology is expected to drive broader adoption of the product.
Read more →NRXS▲ +21.8%on this news· ran to +34% by day 1
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
NeurAxis, Inc. announced a new medical coverage policy from a major health insurer, enhancing access to its IB-Stim technology for 18 million members. IB-Stim, FDA-cleared for treating functional abdominal pain in pediatric patients, addresses a significant unmet need. The company aims to leverage this coverage to boost commercialization and physician adoption.
Read more →NRXS▲ +21.8%on this news· ran to +34% by day 1shared move
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
NeurAxis, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference with a webcast presentation and one-on-one investor meetings. The event is scheduled for September 29-30, 2026. NeurAxis focuses on neuromodulation therapies, particularly its FDA-cleared IB-Stim technology for treating functional abdominal pain in IBS and related conditions.
Read more →NRXS▲ +6.4%on this news
NeurAxis Expands Payer Coverage with New Policies
NeurAxis, Inc. has announced expanded medical policy coverage for its IB-Stim treatment, increasing access for over 500,000 lives in the Mid-Atlantic region. The company is progressing towards comprehensive nationwide coverage and emphasizes the clinical value of its FDA-cleared PENFS technology. IB-Stim addresses a significant unmet need in pediatric patients with abdominal pain disorders.
Read more →NRXSNeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
NeurAxis, Inc. will report its second quarter 2026 financial results on August 11, 2026, before market open. A conference call is scheduled for the same day at 9:00 am ET to discuss the results. The company focuses on neuromodulation therapies, particularly its IB-Stim technology, which is FDA cleared for various gastrointestinal conditions.
Read more →NRXSNeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
NeurAxis reported a record financial performance for Q1 2026, with revenues increasing by 80% year-over-year to $1.6 million. This growth was driven by the effective Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, which improved payor coverage. The company also achieved FDA clearance for treating abdominal pain in children, further expanding its market potential.
Read more →NRXSNeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
NeurAxis, Inc. will report its first quarter 2026 financial results on May 12, 2026. A conference call is scheduled for the same day at 9:00 am ET to discuss the results. The company focuses on neuromodulation therapies for chronic conditions and has FDA clearance for its IB-Stim technology.
Read more →NRXSNeurAxis Expands Payer Coverage with Four New Medical Policies
NeurAxis, Inc. has announced that four additional health insurers have adopted medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, IB-Stim, which now has the potential to benefit approximately 1.25 million covered lives. The company emphasizes its commitment to making this non-invasive treatment for functional abdominal pain more accessible and affordable. However, the recent audit report raises concerns about the company's financial stability, noting substantial doubt regarding its ability to continue operations. Despite the risks, NeurAxis continues to see strong momentum in expanding insurance coverage.
Read more →NRXS▼ -5.7%on this news
NeurAxis, Inc. Announces Preferred Stock Dividend
NeurAxis, Inc. has announced a stock dividend on its Series B Preferred Stock, declaring that holders of record will receive common stock based on accrued and unpaid dividends. The dividend is set to be issued on April 28, 2026, with approximately 510,605 shares expected to be distributed. This move signifies NeurAxis's commitment to its shareholders as it continues to focus on developing neuromodulation therapies for chronic conditions.
Read more →NRXSNeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
NeurAxis, Inc. reported strong financial results for the fourth quarter and full year 2025, with revenues increasing 33% year-over-year to $3.6 million. Key achievements included receiving FDA clearance for abdominal pain treatment and a Category I CPT code assignment for its IB-Stim technology. Despite the revenue growth, the company experienced an increased operating loss attributed to higher sales expenses and a one-time legal settlement. Management highlighted plans for expanding medical policy coverage and scaling adoption of their therapies moving forward.
Read more →NRXS▲ +5.9%on this news
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
NeurAxis, Inc. will announce its fourth quarter and full year 2025 financial results on March 19, 2026. A conference call is scheduled for the same day at 9:00 am ET to discuss these results. The company specializes in neuromodulation therapies and has FDA clearance for its IB-Stim technology, aimed at treating chronic conditions.
Read more →NRXSNeurAxis Achieves Major Milestone with AMA Category I CPT Code Now in Effect, Establishing a Permanent Reimbursement Pathway
NeurAxis, Inc. has announced the implementation of a Category I CPT code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, marking a significant milestone in the company’s commercial strategy. This new coding establishes a permanent reimbursement pathway, facilitating broader acceptance and utilization of the therapy in medical practices. With the CPT code now in effect, NeurAxis expects to enhance patient access to care and improve alignment with payers, ultimately supporting future revenue growth. The company's management is optimistic that this breakthrough will strengthen their business foundation and expand coverage opportunities.
Read more →NRXS▲ +11.8%on this news· ran to +40% by day 1
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
NeurAxis, Inc. has announced a significant medical coverage policy for its IB-Stim device, expanding access to approximately 45 million health plan members. This FDA-cleared neuromodulation therapy targets functional abdominal pain in pediatric patients, addressing a critical unmet need. The company aims to secure additional coverage from major insurers and anticipates revenue growth supported by a new CPT code and clinical guidelines.
Read more →NRXSNeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
NeurAxis, Inc. has secured a Veterans Affairs Federal Supply Schedule contract, effective December 1, 2025, allowing broader access to its IB-Stim device for treating functional abdominal pain. This award positions NeurAxis as a federal contractor, enhancing its commercial pathway into the VA health system. The company anticipates that this development will support sustained commercial momentum as it enters 2026.
Read more →NRXS▲ +7.9%on this news
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
NeurAxis, Inc. has announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology in Michigan, impacting around 566,000 lives. This expansion increases the total national coverage to approximately 55 million lives. The IB-Stim device is FDA-cleared for treating functional abdominal pain in pediatric patients, filling a critical gap in available therapies.
Read more →NRXS▼ -5.9%on this newsshared move
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
NeurAxis, Inc. reported a 22% increase in revenues for Q3 2025, reaching $811,000. The company anticipates significant growth in 2026 following the introduction of a CPT Category I code for its IB-Stim therapy. Despite a decline in gross margin and increased operating losses, management remains optimistic due to recent FDA clearance for expanded indications.
Read more →NRXS▼ -5.2%on this news
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
NeurAxis, Inc. will report its third quarter 2025 financial results on November 11, 2025. A conference call is scheduled for the same day at 9:00 am ET to discuss the results. The company focuses on neuromodulation therapies, including its FDA-cleared IB-Stim™ therapy for adolescents with IBS.
Read more →NRXS▼ -8.6%on this news· ran to -21% by day 3
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis, Inc. has received FDA 510(k) clearance for its PENFS technology to treat functional dyspepsia and associated nausea in patients aged 8 and older. This marks the first FDA approval for a treatment specifically targeting functional dyspepsia in adults. The technology provides a non-surgical option for managing chronic abdominal pain, potentially improving the quality of life for many patients.
Read more →About Neuraxis, Inc.
Headquarters11611 N. MERIDIAN ST, CARMEL, IN, 46032
BIOPHARMAWATCH ELITE PLUS
Trade the next NRXS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime